Charles Schwab Investment Management Inc Travere Therapeutics, Inc. Transaction History

Charles Schwab Investment Management Inc

$515 Billion
Q3 2024

A detailed history of Charles Schwab Investment Management Inc transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 567,409 shares of TVTX stock, worth $11.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

567,409

Previous 568,593 0.21%

Holding current value

$11.5 Million

Previous $4.67 Million 69.87%

% of portfolio

0.0%

Previous 0.0%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$7.89 - $15.21 $9,341 - $18,008	-1,184 Reduced 0.21%	567,409 $7.94 Million
Q2 2024 Aug 12, 2024	BUY	$5.26 - $8.28 $69,016 - $108,641	13,121 Added 2.36%	568,593 $4.67 Million
Q1 2024 May 08, 2024	BUY	$7.18 - $9.82 $114,772 - $156,972	15,985 Added 2.96%	555,472 $4.28 Million
Q4 2023 Feb 06, 2024	SELL	$5.44 - $9.5 $143,790 - $251,104	-26,432 Reduced 4.67%	539,487 $4.85 Million
Q3 2023 Nov 08, 2023	BUY	$7.64 - $17.25 $195,324 - $441,013	25,566 Added 4.73%	565,919 $5.06 Million
Q2 2023 Aug 09, 2023	BUY	$15.3 - $22.61 $581,751 - $859,700	38,023 Added 7.57%	540,353 $8.3 Million
Q1 2023 May 11, 2023	BUY	$17.82 - $22.89 $698,882 - $897,722	39,219 Added 8.47%	502,330 $11.3 Million
Q4 2022 Feb 13, 2023	BUY	$18.47 - $26.14 $4,968 - $7,031	269 Added 0.06%	463,111 $9.74 Million
Q3 2022 Nov 14, 2022	SELL	$22.91 - $28.63 $167,357 - $209,142	-7,305 Reduced 1.55%	462,842 $11.4 Million
Q2 2022 Aug 15, 2022	SELL	$20.94 - $30.01 $36,289 - $52,007	-1,733 Reduced 0.37%	470,147 $11.4 Million
Q1 2022 May 13, 2022	BUY	$23.61 - $30.6 $320,151 - $414,936	13,560 Added 2.96%	471,880 $12.2 Million
Q4 2021 Feb 11, 2022	SELL	$24.34 - $31.17 $135,306 - $173,274	-5,559 Reduced 1.2%	458,320 $14.2 Million
Q3 2021 Nov 16, 2021	SELL	$12.98 - $25.03 $2.29 Million - $4.41 Million	-176,236 Reduced 27.53%	463,879 $11.3 Million
Q2 2021 Aug 16, 2021	SELL	$14.11 - $26.4 $501,398 - $938,124	-35,535 Reduced 5.26%	640,115 $9.34 Million
Q1 2021 May 17, 2021	BUY	$23.37 - $31.77 $2.74 Million - $3.73 Million	117,340 Added 21.02%	675,650 $16.9 Million
Q4 2020 Feb 16, 2021	BUY	$19.17 - $27.87 $10.7 Million - $15.6 Million	558,310 New	558,310 $15.2 Million

Others Institutions Holding TVTX

# of Institutions

196

Shares Held

84.9M

Call Options Held

776K

Put Options Held

900K

View Full List

About Travere Therapeutics, Inc.

Ticker TVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,173,600
Market Cap $1.3B
Description
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...

More about TVTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account

Charles Schwab Investment Management Inc Travere Therapeutics, Inc. Transaction History